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ABSTRACT
Cannabidiol, also known as CBD, first gathered national spotlight after Charlotte
Figi and her mother Paige were able to find two physicians willing to prescribe CBD to
treat Charlotte’s seizures. Charlotte suffered from Dravet Syndrome, but was able to find
relief from CBD, which decreased the number and severity of her seizures. This sparked
national interest and was the catalyst that lead to research and changes surrounding CBD
uses and legality. Cannabidiol is a single cannabinoid that is found within the Cannabis
sativa plant family—the same family that includes marijuana. This cannabinoid differs
from tetrahydrocannabinol (THC) and does not provide a high to its users, which depends
on the receptors activated by each cannabinoid.
To date, Epidiolex® is the only FDA approved drug which contains non-synthetic
cannabidiol extract. The drug has a very narrow indication and is approved only for rare
forms of pediatric seizures such as Lennox-Gastaut Syndrome and Dravet Syndrome.
Non-FDA-approved uses of CBD vary based on anecdotal evidence. Some commonly
reported uses for CBD include easing anxiety, helping with sleep, and clearing up acne or
skin blemishes. Thousands of CBD products that do not have FDA approval are on the
market and are available to consumers. This largely came about due to the passage of the
2018 Farm Bill, which made hemp federally legal in the United States—essentially
federally legalizing CBD. However, not all states have legalized all forms of CBD.
For example, Mississippi enacted Harper Grace’s Law in 2014 which approves
cannabidiol in limited quantities and indications if prescribed by a licensed physician. It
also led to clinical trials for CBD in epilepsy to be conducted at the University of
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Mississippi Medical Center in Jackson, Mississippi, presumably for a competitor product
of Epidiolex®. However, no other CBD products are legal for use in Mississippi, despite
the prevalence of CBD stores and CBD products in state-permitted pharmacies. Things
may change, however, as Mississippi is set to have medical marijuana on its ballot in
November of 2020. If passed, this would not only allow medical marijuana to be
prescribed for certain medical indications, but presumably CBD as well.
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INTRODUCTION
Charlotte’s Web
Charlotte Figi was one of two children born to Paige Figi on October 18,
2006. Charlotte and her twin brother were born healthy and happy. Then three months
later Charlotte began having seizures. Her first seizure was 30 minutes long, but soon her
seizures would last hours and frequently land her in the hospital. No doctor could give
her a diagnosis. No tests were coming back with positive results. Yet, Charlotte was still
having constant seizures, and the seizures were becoming increasingly severe in length
and strength. Finally, one doctor suggested that Charlotte might have Dravet Syndrome.
Dravet syndrome is an exceptionally rare case of intractable epilepsy. This was the first
attempt at a diagnosis for Charlotte and soon she was seeing a neurologist at the
Children’s Hospital in Colorado who conducted a scan for the SCN1A gene mutation
which is common in Dravet syndrome cases. For the first time, a test came back positive.
As devastating a diagnosis as it was, Charlotte’s mother, Paige, was relieved to finally
have an answer. Now she could finally go about finding the next step to help her
daughter. A Dravet Syndrome specialist in Chicago suggested Charlotte begin a
ketogenic diet, which is high in fat and low in carbs. This would cause her body to
produce more ketones which naturally suppress seizures (Young).
At first there was a noticeable drop in the number of seizures Charlotte
had. However, there was also a noticeable decrease in her bone density and she
experienced reduced immunity. Two years into the diet, her seizures came back. Paige
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began researching anything and everything having to do with Charlotte’s condition. She
happened upon an article about a boy from California treating his Dravet syndrome with
cannabis. At first Paige was hesitant, but when weighing her options, she decided it was
worth trying. The cannabis used for treatment was high in CBD and low in THC, both
different cannabinoids of marijuana. Colorado approved the legalization of marijuana for
eight medical purposes in 2000, one of those purposes being seizures. Paige decided to
apply for the program and plead Charlotte’s case. It was no easy pitch. Because she was
so young (5 years old at the time) no doctor was willing to sign off on it because of her
age and the unknown long-term results. After searching, she found two doctors willing to
approve her program application for the same reason as Paige was willing to apply—
nothing else had worked. Once approved, the results were stunning. Charlotte’s seizures
slowed to two or three times a month, mostly in her sleep. She regained her immune
system and bone density and began developing normally. She continues to take two
doses a day with her meals. The strain of cannabis used to treat her, R4, was named
Charlotte’s Web, representing the tangled path she went through to find a cure for her
seizures (Young).
What is CBD?
Cannabidiol, or CBD as it is commonly known, is a specific cannabinoid found in
plants from the Cannabis sativa family, such as hemp and marijuana. Cannabinoids,
sometimes also referred to as phytocannabinoids, are naturally occurring chemical
substances which possess biological activity (Merriam-Webster). Cannabinoids such as
CBD are chemicals produced by the flowers of the cannabis plant that emulate some of
the natural neurotransmitters of the body, endocannabinoids (Rahn). Endocannabinoids,
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which are present in all vertebrates, are responsible in part for maintaining the
homeostasis of our bodies (UCLA Health). The endocannabinoid system (ECS) helps
mediate the internal cell to cell communication and aids in the stabilization of a variety of
body processes such as metabolism, memory, appetite, stress, pain and sleep (Rahn,
UCLA Health). Endocannabinoids bind to receptors located throughout our bodies. The
receptors are generally divided into Cannabinoid-1 Receptors (CB1) and Cannabinoid-2
Receptors (CB2). The central nervous system, consisting of the brain and nerves, houses
the CB1 receptors while the remainder of the body houses the CB2 receptors.
Understanding how our endocannabinoid system works, including how our receptors
work, has allowed for distinctions to be made among the many various cannabinoids.
The two most common cannabinoids are CBD and THC, known as cannabidiol
and tetrahydrocannabinol respectively. THC is the main psychoactive cannabinoid in
marijuana and other Cannabis sativa plants which provides a “high” to its users
(Holland). This high is present because of THC’s ability to tightly bind CB1 receptors in
the central nervous system, specifically the brain. THC and CBD have very similar
structures and are in fact made up of the exact same composition of elements, only
arranged slightly differently (Holland). Both structures are similar to natural
endocannabinoids made by the body and allow for interaction with CB1 and CB2
receptors. Due to the differences in structures, THC has more of an affinity for the CB1
receptors and CBD has more of an affinity for the CB2 receptors. It is unknown for
certain if CBD will bind directly to the CB1 receptors in the central nervous system, but
it is known that CBD will interact indirectly, lessening the effects of THC and reducing
epileptic seizures (Project CBD). CBD is currently being examined for its medicinal
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properties and as an alternative to other medications for conditions such as chronic pain,
seizures, sleep-disorders, and many more. Currently, Epidiolex® is the only FDA
approved drug on the market containing actual cannabidiol (CBD) from the Cannabis
plant. This approval came on June 25 of 2018, and Epidiolex® is specifically indicated
for treatment of two rare and severe forms of pediatric epilepsy, Lennox-Gastaut
Syndrome and Dravet Syndrome, in patients at least 2 years of age (Commissioner,
Project CBD). There are other drugs on the market such as Marinol, Nabilone, and
Rimonabant which are synthetic cannabinoid drugs that mimic other cannabinoids and
endocannabinoids, but the active components in these medicines are not derived directly
from the Cannabis plant like the phytocannabinoids in Epidiolex® (Rahn).
Non-FDA approved products containing CBD are available as supplements and
vitamins, marketed towards curing various ailments, soothing aches and pains, and even
clearing skin. Among these products consumers will commonly encounter terminology
such as “CBD rich” and “CBD dominant.” While similar sounding, these terms are used
to distinguish differing amounts of THC in products by comparing ratios of
CBD:THC. A product labelled “CBD-rich” has high CBD and THC contents, but there is
usually more CBD than THC (about 4% more dry weight) (Rahn). A product labelled
“CBD-dominant” on the other hand refers to products with an overwhelming amount of
CBD and minimal THC content.
Terms and Classifications
Many terms surrounding CBD are used interchangeably, but are actually distinct
and separate terms and need to be defined. The most common terms are hemp, cannabis,
marijuana, and weed. Cannabaceae, the hemp family, includes the Cannabis genus under
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which distinct species such as Cannabis L. (hemp) and Cannabis sativa L. (marijuana)
fall (Classification). Cannabis the genus can be thought of as a general, encompassing
term that contains multiple subsets including marijuana and hemp (CBD Web). Between
these two, the most easily quantifiable distinction comes with how much THC is present
in the plant. Anything greater than 0.3% THC dry weight qualifies as marijuana.
Anything less than 0.3% THC dry weight qualifies as hemp. Because THC is mainly
produced in the flowering parts of the Cannabis plants, US law denotes hemp as the
stalks, stems, and sterilized seeds of cannabis sativa and marijuana as the leaves, flowers
and viable seeds of Cannabis sativa (Stanford). Weed is one of many slang words
referring to marijuana which has origins in 1930s Harlem, but does not refer to a specific
species at all (Wright).
Scheduling of substances directly relates to their potential for abuse and
dependence and is listed on a scale from I-V with I having the highest potential for abuse
and physiological and psychological dependence and 5 having the least (DEA). Cannabis
has previously been listed as a Schedule I drug since 1970, which implies that there is
currently no medical value or accepted reason for using the substance (DEA).
Hypothesis
The purpose of this narrative review is to determine if the following hypothesis
can be supported: That CBD has potential to clinically treat numerous conditions, but
that such potential needs to be explored in a rigorous and legal way.
Data Collection
Data for this review comes from easily accessible information which is available
to the public. Most of my data can be found online, through various websites that are
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sited throughout this paper and can be found in the references section. Other data came
from magazine readings, advertisements, and personal observations and interactions. My
interactions included informally interviewing store owners who stocked and sold CBD
products, as well as speaking with people who are currently using CBD for their personal
health in some way. These personal anecdotes were compared to anecdotal evidence
from additional online sources.

6

THERAPEUTIC USES OF CANNABIDIOL
Clinical Uses of CBD
Cannabidiol is marketed to heal and improve many ailments, but what does CBD
really treat? There are many personal anecdotes documenting the potential uses of CBD,
but clinical studies and clinical data on cannabidiol are fairly limited. The most
substantial clinical data comes from clinical trials related to the treatment of epilepsy
which lead to the FDA approval of Epidiolex® in June of 2018 (Centers for Drug
Evaluation and Research). An interesting clinical study investigated the effects of the
human endocannabinoid system as a cancer target. The results could have implications in
the use of CBD as a cancer therapy, since CBD interacts with the body’s natural
endocannabinoid system receptors CB1 and CB2 (Laezza, et al.) However, this
preliminary data needs to be researched more before drawing firm conclusions. Sativex
is a new investigational drug currently in clinical trials which aims to reduce pain in
cancer patients with a poor response to opioid medications. Sativex has THC as well as
CBD components (GW Pharmaceuticals).
There have also been a few pre-clinical studies to explore the effectiveness of
CBD in neurological diseases such as Alzheimer's Disease, Parkinson’s Disease, and
Multiple Sclerosis (Mannucci, et al.). The findings suggested that because of the antiinflammatory qualities of CBD and the antioxidant properties, CBD could be a
breakthrough in neuroprotective agents, but there would need to be clinical studies
conducted and more data found before this could be confirmed (Mannucci, et al.). Below
is a 2019 chart from Hemp Industry Daily, which shows highlights the pharmaceutical
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interest in clinical research of cannabidiol as well as which companies have completed,
active, or future study trials lined up. GW Pharmaceuticals currently has the highest
number of completed trials and is the company that completed clinical trials for
Epidiolex®. GW pharmaceuticals is also the company currently conducting trials for
Sativex.
Figure 1: US Pharmaceutical Companies

From: https://hempindustrydaily.com/hemp-cbd-companies-lining-up-universityresearch-to-validate-anecdotal-evidence/
The current clinical data on the uses of CBD is fairly limited, which has led to
increased attention on personal anecdotes of success/treatment with CBD and products
containing CBD. A lot of information circulating through the general population
concerning the medicinal properties of CBD come from personal testimonies of how the
compound has worked to fix their problems. There are common trends and abundant
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stories of CBD helping with the same conditions, such as anxiety, sleep disorders, and
chronic pain, to list a few. Despite the wide array of potential treatments, CBD
surprisingly is not reported to have many side effects. These anecdotal stories provide a
starting point to begin researching the effects of CBD in a clinical setting to determine
the true range of this drug. A few examples from Centennial Spotlight include stories on
how CBD helps with:
•

Improved sleep

•

Reducing aches and pains, arthritis, post-workouts

•

Anti-inflammatory skin care creams, anti-aging creams

•

Relaxing, reducing anxiety and stress, PTSD alleviation

While none of these are confirmed indications for the use of cannabidiol (currently
seizures are the only medically acceptable indication with clinical data), it is interesting
to notice how the general population is seeing effects of cannabidiol in their everyday
lives (Centennial Spotlight). Although none of these anecdotal stories are backed by
clinical data as of now, they may pave the way for new areas of research related to the
uses and benefits of CBD.
Epidiolex®
Epidiolex®, the only FDA approved drug containing non-synthetic CBD derived
directly from Cannabis plants, is indicated for two severe and rare forms of pediatric
epilepsy, Dravet syndrome and Lennox-Gastaut syndrome (Center for Drug Evaluation
and Research). This schedule V drug is approved in patients over 2 years of age and is
available as a liquid solution which is to be taken twice daily for seizure control
(Slowiczek). Doses are based on a patient’s weight, severity of seizures, and tolerability
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of the drug. Doses can be increased if needed, but it is recommended to start at a low
dose to gauge patient response. The clinical studies results showed a statistically
significant (p value of 0.001) decrease in seizures for patients taking Epidiolex® than for
patients on a placebo. This clinical study did not take into account race because 86
percent of participants were white, but was shown to work similarly in males and females
and to work similarly in those above and below the age of 18. There were four clinical
trials that led to the approval of Epidiolex® by the FDA. Double-blind clinical trials
(neither health care provider or patient knew what drug was being received) were done in
Europe and the US and consisted of 550 patients over 58 sites. The patients were about
50/50 male to female (real values are 46/54 M/F).
How were the trials designed? Epidiolex® was evaluated throughout four clinical
trials; the first three evaluated safety and efficacy, the fourth was purely testing for the
safety of the drug. The subjects/patients in the first two trials suffered from LennoxGastaut syndrome and were having uncontrolled seizures due to lack of effectiveness on
their current treatments. These subjects were assigned randomly into a treatment and
placebo group in a double-blind study. Both groups took two doses per day, and doses
for both groups were increased every other day for two weeks to reach the desired
dose. After reaching the desired dose, subjects remained there for 12 weeks. The
difference in the number of seizures between the placebo and treatment group and their
respective baselines were measured and used to determine the efficacy of Epidiolex®.
Trials three and four were conducted for patients who suffered from uncontrolled
seizures on their current medication for Dravet syndrome. Trial 3 was conducted the
exact same as trials 1 and 2, but for patients with Dravet syndrome. Trial 4 was a study
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to determine the safety and side effects of certain doses of Epidiolex®. In this doubleblind study, subjects were randomly assigned to take one of three possible doses of
Epidiolex® twice daily for 3 weeks.
Mild and severe side effects may occur when taking Epidiolex®. Because
Epidiolex® was approved through clinical studies, these side effects are known. Mild
side effects include feeling drowsy or lacking energy, generally feeling under-theweather, loss of appetite, and diarrhea. Mild side effects are expected to lessen over the
course of a few days to a couple of weeks. While severe side effects of Epidiolex® are
rare, reported side effects included sedation, liver problems, severe allergic reactions, and
suicidal thoughts (Slowiczek). The risk of most side effects is increased with higher
doses of Epidiolex®.
CBD and Animals
There are no currently approved cannabidiol containing drugs for animals. While
many people use CBD for anxiety and other common conditions of animals, it is
currently illegal under the Food, Drug, and Cosmetic Act (FDCA). The FDCA states that
any product containing CBD, THC, or other components of marijuana are currently not
allowed in food of any sort for human or animal consumption (FDA). As far as
veterinary recommendations, the topic must be brought up by the patient before the vet
may endorse trying CBD products for pets (Consumer Reports). If looking to try
cannabidiol for a pet, recommendations are to seek out products marketed for animals
that avoid other ingredients which may be toxic to animals. Other recommendations
include dosing gradually and watching to see how each pet responds individually to
treatment with CBD. Currently there is even less known about the safety and
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effectiveness of CBD in animals than there is in humans. This is an emerging market
which is expanding as pet owners’ anecdotal stories of pets with lessened anxiety,
improved movement due to decreased pain of arthritis, and decreased seizure activity
grow (Consumer Reports).
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FEDERAL REGULATION OF CANNABIDIOL
Overview
While CBD is found virtually everywhere now, ranging from gas stations to
dispensaries to CBD specific stores, the legality surrounding CBD is not clear. There is a
lot of uncertainty on which laws apply in which states and where the ever-changing fine
line between legal and illegal stands.
Agricultural Improvement Act of 2018 (2018 Farm Bill)
Every five years, Congress passes a bill stating and amending policies governing
national agriculture, nutrition, conservation, and forestry. The Agricultural Improvement
Act of 2018 is the current version, which will last through 2023. It is often cited and
commonly known as the “2018 Farm Bill.” This bill is of interest because of the extent
to which hemp is included and discussed. The term “hemp” appears 48 times throughout
the 2018 Farm Bill.
The term hemp is clearly defined in section 11101 of Title 11 and references
section 297A of the Agricultural Marketability Act of 1946 which states that hemp is
defined as any part of the plant Cannabis sativa L. with less than 0.3% delta-9
tetrahydrocannabinol (THC) concentration by dry weight. A key distinction concerning
definitions is addressed later in section 12608 of Title 12, where it is noted that hemp
does not include “marihuana” and that the Schedule 1 status of tetrahydrocannabinol
(THC), found in the Controlled Substances Act, will not apply to the minimal amount of
THC found in hemp as it was defined earlier. After clarifying the definition of hemp,
sections 11101, 11106, 11112 and 11120 of Title 11 all make varying amendments to
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include hemp under crop insurance (Agricultural Hemp Solutions). This extension
protects farmers under the Federal Crop Insurance Act which assists farmers in
production and crop termination or crop failure (Hudak).
The 2018 Farm Bill amends the Agricultural Marketing Act of 1946 to allow
states a chance to propose a plan for growing and producing hemp, which can then be
sent to the United States Department of Agriculture (USDA) for approval. In order for
the USDA to approve a state’s proposed plan, the plan must state where the hemp will be
grown, how the THC levels will be tested, and how plants with THC levels exceeding
0.3% will be disposed of. If approved, that state may then grow hemp. If denied, that
state must comply with federal laws and regulations (United States Senate Committee on
Agriculture, Nutrition, and Forestry).
Research involving hemp is addressed in sections 7415 and 7125 of Title 7.
Section 7415 deals with the legitimacy of industrial hemp research and requires a study
and report on the “economic viability” of the hemp industry (domestic production and
sales of industrial hemp) in the United States. Section 7125 has been changed to include
hemp in alternative and supplemental crops on which research projects can be conducted.
It is important to note that while the 2018 Farm Bill does make changes to the production
of hemp and allow research, it specifically notes in section 10112 that those amendments
do not authorize interference with current laws on interstate commerce regarding hemp.
The 2018 Farm Bill provides a clear definition of hemp, allows growth and
production of hemp if through a USDA approved plan, extends protection for researchers
and farmers who choose to work with hemp, and legalizes hemp under specific
conditions and with considerable restrictions and regulations (United States Senate
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Committee on Agriculture, Nutrition, and Forestry). This bill does not have anything to
do with state-legal cannabis programs, which are still illegal under federal law (Hudak).
In regards to cannabidiol (CBD), this bill removes hemp-derived products from Schedule
I status, which effectively legalizes CBD. However, nowhere is it explicitly stated that
CBD is legalized. In fact, according to the 2018 Farm Bill, only very specific batches of
CBD would be considered legal. Only CBD produced following every part of this bill,
following all federal and state regulations, and produced by a licensed grower would be
considered legal. Any other form of CBD products (even if produced under state-legal or
medical cannabis programs) are considered illegal under federal law (Hudak). This is a
gray area where technicalities are difficult to enforce, and manually determining the
origin of all CBD-containing products is unrealistic. Another gray area is that although
the 2018 Farm Bill essentially legalized CBD, most CBD products are still in violation of
the Food Drug, and Cosmetic Act.
Food, Drug, and Cosmetic Act
The Food, Drug, and Cosmetic Act (FDCA) is a set of laws giving the FDA
authority to monitor the safety of foods, drugs, medical equipment, and cosmetics that
was enacted by Congress in 1938 (Wikipedia). The FDA website has stated that it has
only approved one drug containing CBD, Epidiolex®, and specifically notes that it is
currently illegal to market and sell CBD in addition to food or by labeling it as a dietary
supplement (FDA). The website also notes that CBD products are being marketed
without proven health benefits, with potentially untrue claims, and under unknown
quality, but makes a specific point to mention food. The FDA strongly encourages
pregnant women to avoid any form of marijuana while pregnant (including THC and
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CBD isolates). The U.S. Surgeon General advised to avoid THC since the substance may
cross into the placenta and affect fetal brain development as well as linger in breastmilk.
There is no conclusive evidence on CBD, so it is recommended for mothers to avoid it as
well.
Interstate commerce of CBD or THC directly violates the Food, Drug, and
Cosmetic Act. Under the Q&A section of their website, the FDA states that food with an
active drug ingredient of an approved drug or ingredients which are currently under
clinical investigation are prohibited from interstate commerce. This is interesting when
taken into account with internet sales of CBD. For the most part the FDA has been
turning a blind eye and companies like Oki are being crafty with marketing, labeling their
CBD-infused waters as having “active hemp ingredients” (Reiley). However, the FDA
sent out twenty-two warning letters to companies in 2019.
Warning Letters from the FDA
The FDA website has a list of companies to which it has issued warning letters
concerning unapproved new drugs and supplements which contain cannabidiol. Most
recently updated in November of 2019, the FDA sent letters to a total of twenty-two
companies located in California, Texas, Oklahoma, Colorado, New York, Oregon,
Florida, North Carolina, Arizona, Kentucky, Arkansas, Maine, New Jersey, and
Washington for that calendar year (FDA). Companies marketing products with
unapproved claims or untested amounts of CBD were sent a letter addressing the
marketing and selling of cannabidiol products. As an example, the letter to Koi CBD
LLC in California was sent a letter on the 22nd of November 2019 and followed the
following format.
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The warning letter began by addressing the products of interest by name and the
claims of each product. The next issue to be covered was the misbranding of CBD
containing products under varying sections of the Food, Drug, and Cosmetic Act
(FDCA). Koi CBD LLC was also selling CBD products targeted to treat animals, which
was in violation of the FDCA. The letter goes on to mention violation of interstate
commerce law under the FDCA and the labeling and definition restrictions for dietary
supplements, which CBD does not currently fall under. The next header is titled
“Unapproved New Drugs” and notes specific instances on Koi CBD LLC’s website
which claim to know and promote benefits of CBD. Lastly, the warning letter addresses
adulterated human and animal foods. Each letter follows this same general outline.
Although these warning letters were sent out, the FDA still struggles to enforce
certain rules on companies that choose to market CBD products. Dr. Amy Abernethy,
principal deputy commissioner of the FDA and co-chair of CBD Policy Working group
founded by the FDA, noted two important points in her testimony to Senate Agriculture
Committee on July 25 of 2019. First, she acknowledged that full regulation of CBD
products as ingredients in food or supplements would require new laws from Congress,
which could likely take up to five years to form and pass (Page). Second, she implied
that the FDA was hesitant to legitimize current over the counter CBD products. This
would decrease the need for prescription drugs like Epidiolex®, which would deter
pharmaceutical companies from investing in the research to determine the full extent of
what CBD could treat or help cure. There is not enough current research available for the
FDA to determine the safety and efficacy of CBD for certain populations and ailments, so
pharmaceutical companies’ interest in the product is necessary to drive clinical trials
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(Page). Dr. Abernethy did concede that for the most part the FDA is turning a blind eye
to the current CBD industry and is mainly focused on enforcing laws related to the
marketing of cannabidiol. Products containing CBD which are marketed with
“unsubstantiated therapeutic claims” are the main concern of the FDA at this time (Page).
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STATE REGULATION OF CANNABIDIOL
Just like with medical and recreational marijuana, states vary in their allowance of
consumer use of CBD.
Figure 2: US State Legalization Map

From: https://commons.wikimedia.org/w/index.php?curid=2370050

This is a current map as of 28 March 2020, from Wikipedia. The blue states have
fully legalized marijuana including CBD, while the green states will allow marijuana to
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be used for medical purposes. Differentiating between the green states, the light green
states have legalized medical marijuana use as long as there is a low level of THC
(indicating high levels of CBD), while the dark green states are unconcerned with the
amount of THC. Finally, the gray states have not legalized marijuana or cannabidiol in
any form, adult use or medical use. The states marked with a red letter D have
decriminalized marijuana including cannabidiol (Wikipedia).
Special State Laws of Interest
While most states have legalized hemp-derived CBD for seizures and epilepsy
after the Farm Bill was revised in 2018, each state has its own particular rules and
regulations regarding cannabidiol. The source (hemp or marijuana), as well as the
percentages of THC and CBD, and indications of CBD are the main categories to vary
depending on the state.
California has legalized CBD for medical and recreational use, but prohibits the
addition of CBD as a food ingredient until approved by the FDA as a safe ingredient,
additive or supplement (CBD Project Awareness). This rule applies to food intended for
human consumption as well as animal or pet consumption. An interesting way current
businesses are evading this rule is by offering CBD as a side item on menus. A CBD
shot can be ordered and added to food or drink by the customer. This is occurring in
other states as well such as New York.
Delaware has also legalized medical use of CBD from hemp and marijuana but
requires all patients as well as their caregivers to have an ID card that allows them to
possess a maximum of 6 ounces of CBD. The medical CBD from marijuana cannot have
any more than 7% THC. South Carolina however, requires CBD products to have 98%
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CBD and only 0.9% of THC (CBD Project Awareness). This is an area in which states
vary greatly on what is allowed. Hemp by definition in the 2018 Farm Bill is a strain of
cannabis which has less than 0.3% THC; however, especially with states that have
legalized CBD from marijuana this value varies.
Minnesota and New Mexico have added specific qualifying medical conditions to
their lists of approved reasons for prescribing CBD. A few of the usual conditions
include epilepsy, end-stage cancer, multiple sclerosis and Parkinson’s disease.
Minnesota approved CBD for Alzheimer’s and obstructive sleep apnea while New
Mexico was the first state to approve CBD for post-traumatic stress disorder (PTSD)
patients (CBD Project Awareness).
Idaho is one of three states that currently has restrictions on all forms of cannabis
and CBD, even after the 2018 Farm Bill which legalized hemp on a federal level.
Epidiolex®, the only FDA approved drug containing CBD, is the only exception to this
rule. This creates a significant gray area for Idaho citizens who may be able to use CBD
legally under federal law but not under state law (CBD Project Awareness).
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MISSISSIPPI REGULATION OF CBD
Harper Grace’s Law
Just as Charlotte Figi was the catalyst for change at the national level, Harper Grace
Durval was the catalyst for change at the state level in Mississippi. Harper Grace Durval
began having seizures around 6 months of age and was diagnosed with Dravet
Syndrome—the same diagnosis that Charlotte received (Gates). Harper Grace’s mother,
Ashley Durval, advocated for the legalization of CBD treatments in Mississippi for
epileptic seizure patients like her daughter. She stated that the current medications
simply do not work and that they are quickly running out of options for anti-seizure
medicines (WMC-TV).
Harper Grace’s condition and Ashley Durval’s persistence in advocating for CBD use
for severe epileptic patients in Mississippi ultimately lead to the passing of Harper
Grace’s Law, signed into law in April of 2014 by Governor Phil Bryant (Wikipedia). It
originated as House Bill 1231 and passed with a majority vote in both the House and
Senate. Harper Grace’s Law allows cannabidiol in very limited context to be obtained
from a physician who is licensed to practice in Mississippi. The CBD allowed can be in
either oil or resin form from a cannabis plant with at least 15% cannabidiol for oils or 50
mg of cannabidiol per milliliter for diluted resins and a maximum of 0.5%
tetrahydrocannabinol or THC content (Mississippi Legislature, Wikipedia). Additionally,
the CBD must be obtained or tested specifically through the National Center for Natural
Products Research located at the University of Mississippi and be dispensed by the
pharmacy at the University of Mississippi Medical Center in Jackson, Mississippi. The
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law is reserved for patients with “debilitating epileptic condition(s)” (FindLaw). Harper
Grace’s Law is one of the stricter laws regarding medicinal cannabis use among the states
that have approved CBD for medical purposes (Wikipedia).
UMMC Clinical Trial
As of 2017, even after the passing of Harper Grace’s Law, Mississippi still did not
have the final approval needed from the federal government to begin clinical trials at the
University of Mississippi Medical Center (UMMC) in Jackson, Mississippi (Gates). Dr.
Brad Ingram, the director of the Pediatric Comprehensive Epilepsy Center at UMMC,
would be the one to oversee a small trial (roughly 5-10 patients) of CBD oil in severe
seizures of young children if the 32-page proposal submitted to the FDA were approved
(Gates). He noted that while a lot of work had gone into creating the proposal, federal
approval is ultimately out of anyone’s hands. The approval process includes three federal
agencies: The National Institutes of Health (NIH), the Food and Drug Administration
(FDA), and the Drug Enforcement Agency (DEA).
Then in November of 2018 and UMMC had received the necessary approval from
the DEA and FDA to begin trials. Dr. Ingram stated that the study would be six months
long with a maximum of ten patients and aimed to treat the “sickest of the sick” with
“compassionate care” (Oeth). A secondary consideration with a short, small trial was
that of product availability after the study. No one wants to be given a drug that works
and then told that they will no longer have access to CBD. Once the cannabidiol is
produced and checked for quality, it is diluted and dosed using pharmaceutical grade
sesame seed oil (Oeth). The study produced excellent results, with most patients
experiencing a drop in the number of seizures per month and all experiencing an
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increased quality of life. The current drug and dosages were not seen to cause any
damage to developing brains or tolerability issues in the patients. This clinical trial has
been granted a one-year extension in the summer of 2019 and will be reassessed in the
summer of 2020. The FDA extension will allow more development of treatments for
epileptic seizure patients who have not had success with traditional seizure drugs (Oeth).
Technically, this trial provides the only current legal access to cannabidiol in
Mississippi. So why are there so many products and stores openly selling and promoting
CBD products, even in local pharmacies? This is the gray area of law where enforcement
(or lack thereof), specific marketing, purity, and definitions all come into play.
Medical Marijuana on Mississippi November Ballot
Following all of the attention medical marijuana and CBD have gathered over the
past few years, Mississippi will have Medical Marijuana on the ballot in November of
2020. The group Mississippians for Compassionate Care began an initiative that
gathered 106,000 signatures, more than the 86,000 signatures required, to form Ballot
Initiative 65 which is sponsored by Ashley Durval (Ramseth). The goal is to legalize
medical marijuana use in Mississippi allowing doctors to prescribe for specified
conditions including cancer, epilepsy, multiple sclerosis, and Parkinson’s. If approved,
the Department of Health would regulate medical marijuana treatment centers and
dispensaries. While 77% of Mississippians seem to be in favor of legalizing marijuana
for medical purposes, a few concerns have been raised about the medical legalization
eventually leading to recreational legalization (Ramseth). The other opposing arguments
are that little is known about marijuana and how it interacts with certain medical
conditions.
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CONCLUSION
Cannabidiol holds promise for many different conditions but requires more
clinical testing and research before any conclusions can be drawn. The data explored in
this paper in part, support the hypothesis that CBD holds clinical promise for the
treatment of conditions, and studies are being conducted in a rigorous way that meets
FDA approval in the example of Epidiolex® or may do so in the future such as the CBD
product in clinical trials here at the Universiy of Mississippi. But we also reviewed
accounts of situations whereby CBD is not always being used for clinical conditions that
have support or rigorous studies, or is CBD being used in compliance with local laws,
such as in the state of Mississippi.
The implications of future approvals of CBD are closer than we think. As this
drug becomes more regulated and available from pharmacies, it will be necessary for
physicians and pharmacists to have a current working knowledge of the topic and laws
surrounding CBD as well as the available forms and dosing issues in order to ensure the
best possible patient care.
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